Literature DB >> 25617201

Cost-effectiveness of Xpert MTB/RIF and investing in health care in Africa.

Ivor Langley1, Hsien-Ho Lin2, S Bertel Squire3.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25617201     DOI： 10.1016/S2214-109X(14)70370-5

Source DB:  PubMed          Journal:  Lancet Glob Health        ISSN： 2214-109X            Impact factor:   26.763


× No keyword cloud information.
  4 in total

1.  Molecular diagnosis of central nervous system opportunistic infections and mortality in HIV-infected adults in Central China.

Authors:  Rongrong Yang; Hong Zhang; Yong Xiong; Xien Gui; Yongxi Zhang; Liping Deng; Shicheng Gao; Mingqi Luo; Wei Hou; Deyin Guo
Journal:  AIDS Res Ther       Date:  2017-05-02       Impact factor: 2.250

2.  Clinical Impact and Cost-effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients With Presumptive Pulmonary Tuberculosis in the United States.

Authors:  James F Cowan; Aldine S Chandler; Elizabeth Kracen; David R Park; Carolyn K Wallis; Emelline Liu; Chao Song; David H Persing; Ferric C Fang
Journal:  Clin Infect Dis       Date:  2017-02-15       Impact factor: 9.079

3.  Affordability of Adult Tuberculosis Vaccination in India and China: A Dynamic Transmission Model-Based Analysis.

Authors:  Chathika Krishan Weerasuriya; Rebecca Claire Harris; Matthew Quaife; Christopher Finn McQuaid; Richard G White; Gabriela B Gomez
Journal:  Vaccines (Basel)       Date:  2021-03-11

4.  When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs.

Authors:  Alyssa Bilinski; Peter Neumann; Joshua Cohen; Teja Thorat; Katherine McDaniel; Joshua A Salomon
Journal:  PLoS Med       Date:  2017-10-02       Impact factor: 11.069
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.